Blueprint for progress
12 Jan 2021
1 min read
The approval and launch of the COVID-19 vaccines is a beacon
of hope as we enter 2021. Economic activity across markets has started
normalizing and we will continue to see stable trends and recovery and expect
this momentum to be accelerated, particularly with the rollout of the vaccine.
The generic pharma industry has been focused on ensuring
access of medicines to patients during these tough times and has ensured a
stable supply chain through the pandemic. The industry has also focused on
exploring ways of innovating business models in ways that are more
patient-centric. The industry has leveraged technology to deliver information
and medicines to patients and physicians in the backdrop of reduced in-person
interactions.